Salt Consumption After the Administration of Rapid Questionnaire (MINISAL-SIIA STUDY)
MINISAL-SIIA
A Nutritional Questionnaire in an Adult Italian Hypertensive Population: Effects on Sodium and Potassium Intake (MINISAL-SIIA STUDY)
1 other identifier
interventional
315
0 countries
N/A
Brief Summary
A strong and well-known association exists between salt consumption, potassium intake, and cardiovascular diseases. MINISAL-SIIA results showed high salt and low potassium consumption in Italian hypertensive patients. In addition, a recent Italian survey showed that the degree of knowledge and behavior about salt was directly interrelated, suggesting a key role of the educational approach. Therefore, the present study will aim to evaluate the efficacy of a short-time dietary educational intervention (MINIMAL-ADVICE) on sodium and potassium intake in hypertensive patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable hypertension
Started Jul 2016
Longer than P75 for not_applicable hypertension
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2023
CompletedFirst Submitted
Initial submission to the registry
September 5, 2024
CompletedFirst Posted
Study publicly available on registry
October 21, 2024
CompletedNovember 8, 2024
November 1, 2024
5.5 years
September 5, 2024
November 7, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Urinary Sodium and Potassium excretion (mmol/24h)
Urinary sodium and potassium concentrations (mmol/24h) were measured by ion selective electrode potentiometry and urinary creatinine by a kinetic Jaffe reaction using an ABX Pentra 400 apparatus (HORIBA ABX, Rome, Italy). Quality control was effected using urine-specific reference samples from UrichemGol BIODEV (Milan, Italy).
3 months
Secondary Outcomes (1)
Systolic and Diastolic Blood Pressure (mmHg)
3 months
Study Arms (2)
Control
NO INTERVENTIONthe Control group will not receive any additional information on diet
Dietary educational intervention
EXPERIMENTALThe dietary educational intervention group received dietary education to gradually reduce salt intake (a brief dietary education on the health damage due to excess salt consumption and on behavioural methods to gradually reduce dietary intake, for example at home, reduce the consumption of processed foods, do not bring salt shaker on the table, limit the use of condiments with a high sodium content; out of home, both when eating and when shopping, reduce the consumption of processed foods, check nutritional labels and choose products with lower salt content). In addition, written information was provided.
Interventions
At the end of the baseline examination, the Experimental group received a brief dietary education on the health damage due to excess salt consumption and on behavioural methods to gradually reduce dietary intake, for example at home, reduce the consumption of processed foods, do not bring salt shaker on the table, limit the use of condiments with a high sodium content; out of home, both when eating and when shopping, reduce the consumption of processed foods, check nutritional labels and choose products with lower salt content. In addition, written information was provided. All participants will be clinically followed every month, with potential titration of the antihypertensive therapy. After 3 months of follow-up, the baseline measurements will be carried out again. During the entire study period, subjects will be asked to maintain their lifestyle and report using additional medications.
Eligibility Criteria
You may qualify if:
- Adult hypertensive patients with essential hypertension
- assessment of organ damage
- and stable antihypertensive treatment (lifestyle modifications and/or drug therapy) for at least 6 months
You may not qualify if:
- patients with alteration in nutritional and absorptive status
- glomerular filtration rate lower than 60 ml/min/1.73 m2
- personal history positive for a recent cardiovascular event (less than 6 months)
- atrial fibrillation or flutter, frequent atrial or ventricular premature contractions
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
D'Elia L, Strazzullo P, Del Giudice A, Desideri G, Di Quattro R, Ferri C, Grossi A, Malatino L, Mallamaci F, Maresca A, Meschi M, Casola A, Nazzaro P, Pappaccogli M, Rabbia F, Sala C, Galletti F; MINISAL-SIIA Study Group. "Minimal-Advice" on Salt Intake: Results of a Multicentre Pilot Randomised Controlled Trial on Hypertensive Patients. High Blood Press Cardiovasc Prev. 2025 Mar;32(2):181-190. doi: 10.1007/s40292-025-00704-1. Epub 2025 Jan 30.
PMID: 39883400DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
September 5, 2024
First Posted
October 21, 2024
Study Start
July 1, 2016
Primary Completion
January 1, 2022
Study Completion
January 1, 2023
Last Updated
November 8, 2024
Record last verified: 2024-11